Overview

• Under the June 19 agreement, Lotte Biologics will manufacture antibody drug substance for Ottimo Pharma’s Jankistomig at its 40,000-liter capacity Syracuse Bio Campus in New York.
• The partnership accelerates Ottimo’s operational readiness for clinical trials and IND submission for its PD1/VEGFR2 dual pathway antibody candidate, according to company executives.
• Lotte’s New York facility offers end-to-end CDMO services including cell line development, large-scale manufacturing, and ADC conjugation, backed by approvals from over 62 regulatory agencies.
• Construction is underway on three advanced bio plants in Songdo, South Korea, with the first 120,000-liter reactor facility scheduled to come online by 2027.
• CEO James Park said the Ottimo collaboration validates Lotte’s competitiveness in the global antibody therapeutics market and supports its goal of ranking among the top 10 CDMOs by 2030.